Novartis 'extremely disappointed' with NICE no for Afinitor
This article was originally published in Scrip
Executive Summary
NICE has once again issued draft guidance rejecting Novartis' Afinitor (everolimus), this time in advanced breast cancer, because the drug is "not good value for money."